# inThought Capabilities

September 2020

### **Rare Genetic Disease and Rare Disease**



# What Makes inThought Unique?

### business intelligence

A multidisciplinary team of 16 subject matter experts with deep therapeutic area expertise that provides business intelligence support to pharmaceutical, biotech, and financial companies.

Our decision support uses a variety of data points, both primary & secondary, combined with analysis & insight. This methodology allows clients to triangulate actionable intelligence and adjust strategy.

#### analysis & insight

### **business & science**

We understand the business and science. *in*Thought principals are MDs, PhDs, and MBAs with clinical, research, regulatory, and Wall Street experience.

Our proprietary *in*Vision platform allows clients to have all critical intelligence in one place, customized for their particular key questions and topics, and accessible on demand.

proprietary platform

inThought

### inThought Competitive Intelligence Expertise


inThought is able to support a diverse body of client work.



• BD due diligence

& KOLS

### inVision Dashboard Example



Topic folders organized by theme

#### **Continuous Monitoring Examples (1)** *Email Alerts*

inVision connects CI teams to timely alerts and strategic implications based on therapeutic areas, clinical trials, and MOAs of interest.

r 07, 2020	Source: Clinicaltrials.gov NCT03459443	Alert Sent: on Apr 0g, 2020		
nase 2 stu 3G and IC- articipants 20 instea 1shed bac	ow Alexion, delays completion date for it: dy of danicopan for a 12-month treatmer -MPGN. The study, started in June 2018, i s. The primary completion date is anticipa d of December 2019, and the study comp sk from May 2020 to June 2021.	s proof-of-concept Dar at in patients with is a s recruiting 22 the ated to be in June The oletion date is the	Itysis: hicopan has received orphan drug status for C3G in the US and EU. Iso being developed for PNH and has received Breakthrough rapy designation in US and PRIME designation in EU. It delay in the study can be attributed to COVID-19 and will push ba development and approval of danicopan in C3G. It defines the study can be strial for NSI-566 in ALS	
A	Apr 0g. 2020 Source: Seneca Biopharma Press Rele	ase Alert Sent: Apr 0g, 202		Arch
2 0 0 0 1 1 1 1	Description: Seneca Biopharma held a Type C meeting clinical development plans for NSI-566 in t data and feedback from its phase 1 and ph company believes the drug can move to pi currently in the process of developing the VSI-566 is a spinal-cord derived neural ste rebuild neuronal tissue and secrete growth	reating ALS. With positive ase 2 trials for NSI-566, the hase 3 of clinical study and is protocol for further review. m cell line therapy that helps		

- inThought analysts continually monitor corporate press releases, investor presentations, conference abstracts, and clinical trial records to provide timely analysis of relevant events
- Analysis is customized and includes implications that are specific to the client's portfolio
- These alerts are prioritized on inVision as High, Medium, and Low priorities and emailed to client's CI teams
- inVision allows CI teams to keep a pulse on key therapeutic areas, clinical trials, and MOAs

### **News Alert Example**

#### Biocryst doses first patients in its BCX9930 clinical trial for PNH patients

Mar 05, 2020 Source: Biocryst Press Release

Alert Sent: on Mar 05, 2020

#### Description:

Biocryst started dosing first PNH patients with its BCX9930 in part 3 of its ongoing phase 1 clinical trial. The study is designed evaluate the safety and efficacy of BCX9930 twice daily (BID) in 16 participants for 28 days. Patients are split into two cohorts treated with either a low dose regiment of 50 mg and 100 mg BID for 14 days each or a high dose regiment with 200 mg and 400 mg BID for 14 days each. Key markers including levels of LDH, hemoglobin and reticulocytes will be evaluated. Data is expected to be reported in 2Q2020. BCX9930 is an oral small molecule factor D inhibitor in the complement pathway.

#### Analysis:

In October 2019, Biocryst reported results from the SAD and MAD portions of the phase 1 trial in healthy subjects which showed >90% inhibition of the alternative complement pathway at 1200mg dose. The drug was safe and well tolerated, except occurrence of self-limiting rash in certain subjects in the MAD study.

If Biocryst can show successful proof of concept data from this trial, the company would be able to advance the factor D inhibitor program across other target indications in the complement pathway.





### **Continuous Monitoring Examples (2)** *Email Alerts*

inVision connects CI teams to timely alerts and strategic implications based on therapeutic areas, clinical trials, and MOAs of interest.

#### **Clinical Trial Monitoring**

- Trial results (e.g., press release)
- Trial delays
- Trial completions
- New trials
- Endpoint updates
- Trial size expansions

#### **Investor Presentations**

- Management commentary and strategy
- Q&A capture

#### Earnings Coverage

- Revenue tracking
- Industry trends
- Management commentary and strategy
- Q&A capture

		Mar 30, 2020	Source: ClinicalTrial	ls.gov record NCT02163759	Alert Sent: on Mar 30, 2020
				se 2 HIBISCUS Etrial in ul	cerative colitis
Ozanimod phase 3 trials in Mar 25, 2020 Sources: ClinicalTrials gov record NCT ClinicalTrials gov record NCT ClinicalTrials gov record NCT ClinicalTrials gov record NCT	cord NCT03440372, 03440385, 03464097,	Alert Sent: on Mar 25, 2020		Copy URL Resend Alert	✓Edit Analysis ■Archive
Description: Bristol has extended the phase 3 tri by 2 years. The primary completion studies have been pushed out from 2022, and the primary completion of been extended from April 2021 to M study is also extended and now has 2024. Pharma 4Q2019 Earnings: Zilucoplan 28 Source % Pharma Pres Metase	dates of the two pix February and Marc ate for the mainten larch 2023. The long a primary completi	votal induction ch 2020 to March ance study has g-term extension	the impact of the or action date for the r is today, and increas action today was lar approve a drug in th expected to be app ongoing coronaviru overall drug develo	ears is unlikely to be solely relatingoing pandemic likely contribi- esubmitted NDA for ozanimod singly looks to have been missing egy viewed as a betluwether for emiddle of a pandemic. Ozan roved, but any delay to its apprixe s pandemic could have a signification privating program, especially give quired to fulfil the Contingent acquisition.	uted. The target in multiple sclerosis ed. The agency's r the FDA's ability to imod is widely oval due to the icant impact on its en the end-of-year
scription: Pharma 402019 earnings report highlighted the		s at the Leerink Glo	bal Healthcare Con	ference; phase II study of AL	XN1830 (IV) in WAIHA is
In February 2020. Ra Pharma publiched result clinical trial of zilucoplan in patients with gMG Enrollment in phase 3 clinical trial of zilucoplan ongoing, with top-tine results expected in eart (Clinicaltrials gor WCT0415293) in December 2013, first patient dosed in Phase zilucoplan in IMNM, with top-tine results expe- haf of 2020 (Clinicaltrials gor WCT04026302). In January 2020, Ra Pharma received clearand the HEALEY ALS Platform Trial at Mass Genera selected as one of the first clinical candidates in October 2039, Ra Pharma announced its me UCB acquisition of Ra Pharma expected to clo	Description: No update on plans fi are moving ahead wit manufacturing issues safety disclosures wa Are you really going 1 that's something that So we're still moving a manufacturing issues, could put that in patie and we have not seen	es: Alexion at Levrink. Clinicalfinals or ALXN 1830, acknowled in ALXN 1830, acknowled in 2019, Study has starte rranked at hits time. Ito participate in FcRn or s Lyou're going to sort of - thead with 1830. Lotst yeau so we have to redo a who ma sogain, and so that stud any anything that would v	igement confirms they ging they had d and is ongoing, with no should we assume that it's going to pass you by. we did have some CMC le new loss before we dy is started and ongoing varrant any sofely or any arrant any sofely or any	Analysis: During Leerink's Global Healthcare posed to the Alexion management I confirmed they will be moving forw noted the delay was due to manufa express their frustrations with Alexic feel is reflected by a depressed sha	eam in regards to FCRn. Alexion has ard with ALXN 1830 in WAIHA and cturing issues. Investors continue to on's strategic direction, which they

# MMMM

# **Competitive Intelligence (CI) Landscape**

# Sample Work



### **Continuous Monitoring Overview**

Торіс	Slide	
Recent Events	<u>11</u>	
Catalyst Tracker	<u>12</u>	
Disease Overview	<u>13</u>	
Preclinical & Clinical Pipelines	<u>14</u>	
Development Timelines	<u>18</u>	
Clinical Trials Overview	<u>20</u>	
Treatment Guidelines	<u>22</u>	
Efficacy and Safety Overview (Marketed and Pipeline)	<u>23</u>	
Primary Research	<u>25</u>	
Earnings Coverage	<u>28</u>	
	in	Thought

9

### Catalyst Tracker *Sickle Cell Disease*

Event	Expected Timing
NHLBI SCD Advisory Committee meeting	May 31, 2019
Results from full HOPE <b>voxelotor</b> study to be presented at EHA	June 2019
Crizanlizumab regulatory filing	1H19
First SCD patient expected to be infused with CTX001	mid-2019
Voxelotor filing	4Q19
Initiation of confirmatory voxelotor TCD study	2H19
Initiation of phase 3 LentiGlobin HBG-210 study	by end 2019
Inclacumab IND submission	2021
LentiGlobin filing	2022
Note: As of May 31, 2019	inThou

### **Disease Overview: Sickle Cell Disease**

**Disease Overview** 

#### The burden of SCD is significant

- Estimated U.S. prevalence: 100,000 individuals
- Life expectancy (U.S.): 45-58 years
- Annual U.S. healthcare costs: over \$1B

#### **Current therapies are limited**

#### Prevention of complications

- Hydroxyurea
- L-glutamine

#### Treatment of complications

- Pain management
- Antibiotics

#### Curative

- Hematopoietic stem cell transplantation

#### Gene editing/replacement and other drug development and regulatory advances have renewed interest in SCD

- Potential for at least 3 new SCD approvals in the next 3 years (crizanlizumab, LentiGlobin, voxelotor)
- FDA's recent willingness to accept hemoglobin levels as a surrogate endpoint is a watershed moment for the field

# SCD may pose unique challenges for marketers of new agents

- Access to higher priced therapies may be an issue for some SCD patients, especially in developing regions
- SCD patients are perceived to be skeptical of the medical establishment and poorly compliant; these observations could be biased or related to the relative lack of acceptable therapies at present inThought<sup>®</sup>

### Pipeline Overview: Sickle Cell Disease Preclinical Pipeline

Mitapivat; Agios PKR activator	ARQ 092; PO ArQule, Univ or Illinois Pan-AKT inhibitor	<b>EdX-17</b> ; parenteral EpimedX Plant growth factor	DRX-194 DeuteRx Deuterium stabilized single enantiomer	Undisclosed; IV Maxcyte/NIAID Non-viral CRISPR mediated gene therapy
AIC-6020 PHD Biosciences Antioxidant (unspecified)	HBI 002 <sup>;</sup> PO Hillhurst Bio Heme oxygenase modulator	MEDI 6012 (ACP501); IV AstraZeneca Recombinant human LCAT	Anti-inflammatory enzyme inhibitors; PO PHD Biosciences	No designation Homology/Novartis AAV based gene therapy
PNQ 103; PO Impetis Adenosine A2B receptor antagonist	MM-96; PO PHD Biosciences Antioxidant	Vacno SynZyme Technologies Caged NO labeled albumin	No designation; PO Orphagen Pharmaceuticals Orphon nuclear receptor antagonists	No designation Fulcrum Therapeutics Small molecule gamma globin activator
			No designation; IV CSL Behring Plasma derived haptoglobin and hemopexin	No designation; IV Genethon/INSERM, Stanford U Lentiviral gene therapy targeting HBB
			Keap1ASO Ionis Antioxidant genes inducer	No designation; IV Editas CRISPR/CAS9 targeting HBB
			Kif1ASO Ionis gamma-globin inducer through regulation of BCL11A	Sirolimus (rapamycin) Rare Partners, Univ. of Ferrara HbF inducer
			Undisclosed Syros Single gene modulator	


Antioxidant competitor	Small Molecule	Protein	Polysaccharide	Cell Therapy
Annoxidani compenior	Monoclonal Ab	Gene Therapy	RNAi / nucleic	Undisclosed

inThought<sup>®</sup> 12

### Pipeline Overview: Sickle Cell Disease *Clinical Pipeline*

PHASE I	PHASE I/II	PHASE II	PHASE III	MARKETED
Farydak(panobinostat); PO** Novartis HDAC inhibitor	LentiGlobin(BB305); IV Bluebird Bio santi-sickling beta-globin gene	<b>IMR-687;</b> PO Imara PDE9A inhibitor	<b>Brilinta (ticagrelor)</b> ; PO AstraZeneca P2Y <sub>12</sub> platelet inhibitor	Droxia (hydroxyurea); PO Bristol-Myers Squibb SC hemoglobin polymerization inhibitor
<b>EPI-01;</b> PO EpiDestiny/Novo cytidine deaminase inhibitor	CTX-001; IV CRISPR Therapeutics/Vertex CRISPR/Cas9 targeting BCL11A	Sanguinate; IV Prolong dual mode CO and O <sub>2</sub> delivery therapeutic (pegylated Hb)	rivipansel (GMI-1070); IV Pfizer/GlycoMimetics pan-selectin inhibitor (E, L, P)	Siklos (hydroxyurea); PO Addmedica; age: 2+ SC hemoglobin polymerization inhibitor
<b>PF-04447943*</b> ; PO Pfizer PDE9 inhibitor	<b>inclacumab</b> ; IV Global Blood Therapeutics/Roche <i>pan-selectin inhibitor</i>	Sevuparin; IV Modus cell adhesion molecule inhibitor	voxelotor (GBT440); PO Global Blood Therapeutics sickle Hb modulator	Endari (L-glutamine); PO Emmaus antioxidants, protein synthesis modulators
SCD-101; PO Invenux botanical sickling inhibitor	BIVV-003, IV Bioverativ (Shire)/Sangamo ZFN editing targeting BCL11A	<b>Ilaris</b> (canakinumab); IV Novartis <i>IL-1b mAb</i>	crizanlizumab (SELG1/SEG101); IV Novartis P-selectin inhibitor	Small Molecule Monoclonal Ab
				Protein
				Gene Therapy
acute treatment only	1	IW-1701 (olinciguat); PO		Polysaccharide
		Cyclerion (Ironwood) guanylate cyclase agonist		<i>in</i> Thought <sup>®</sup>

#### **Development Timelines: Sickle Cell Disease**





# **Clinical Trial Overview**

# Sample Work




### Clinical Trial Overview: Sickle Cell Disease Voxelotor (GBT440)

16

Trial ID	Phase	Patient Population	Trial Length	Arms	Key Trial Endpoints
HOPE NCT03036813 fully enrolled	3	<ul> <li>Inclusion</li> <li>Age 12-65</li> <li>At least one episode of VOC in the last 12 months</li> <li>Hb ≥ 5.5. and ≤ 10.5 g/dL</li> <li>Exclusion</li> <li>&gt;10 VOCs requiring clinic visit</li> <li>Regular RBC transfusion</li> </ul>	Start Date: Dec. 2016 Primary completion: Oct. 2019 Estimated Length: 2 years, 10 months	<ul> <li>GBT440 (Dose 1)</li> <li>GBT440 (Dose 2)</li> <li>Placebo</li> <li>N=300</li> </ul>	<ul> <li>Primary</li> <li>Proportion with increase of Hb &gt; 1g/dL (baseline to 24W)</li> <li>Secondary</li> <li>Change in hemolysis measures (24W)</li> <li>Annual rate of VOCs (72W)</li> </ul>
NCT02850406 recruiting	2	<ul> <li>Inclusion</li> <li>Age 4-17 (child)</li> <li>HbSS or HbS β0 thalassemia</li> <li>Hb ≤ 10.5 g/dL (parts B &amp; C)</li> <li>Exclusion</li> <li>VOC or ACS (within 14 days of signing consent)</li> <li>Requires chronic transfusion</li> <li>Transfusion in past 30 days</li> </ul>	Start Date: May 2016 <b>Primary completion</b> : May 2022 Estimated Length: 6 years	<ul> <li>Part A – GBT440, PO, 1 day (single dose)</li> <li>Part B – GBT440, PO, QD to 24W</li> <li>Part C – GBT440, PO, QD to 48W</li> <li>N=125</li> </ul>	<ul> <li>Primary</li> <li>PK (Part A)</li> <li>Change in hemoglobin (Part B, 24W)</li> <li>Change in cerebral blood flow via TAMM TCD velocity (Part C, 48W)</li> <li>Secondary</li> <li>Clinical measures of hemolysis</li> <li>TEAEs</li> <li>PK</li> </ul>
NCT02285088 SAD/MAD study completed	1	<ul> <li>Inclusion</li> <li>18-60 (adult) with SCD</li> <li>Healthy volunteers included</li> <li>Exclusion</li> <li>Alcohol consumption restrictions</li> <li>SCD and hemoglobin level &lt;6 g/dL or &gt;10.4 g/dL</li> </ul>	Start Date: Dec. 2014 Primary completion: Mar. 2017 Estimated Length: 2 years, 3 months	<ul> <li>GBT440; PO,QD</li> <li>Placebo</li> <li>N=133</li> </ul>	<ul> <li>Primary</li> <li>AEs</li> <li>Secondary</li> <li>Blood and plasma concentration</li> <li>% of hemoglobin occupied or modified by GBT440</li> </ul>

### Clinical Trial Endpoint Comparison Sickle Cell Disease

The majority of Phase 3 SCD endpoints focus on VOCs; only voxelotor is using change in hemoglobin levels as a primary endpoint in Phase 3. LentiGlobin is also assessing Hb levels in a Phase 1/2 trial, with plans to do the same in Phase 3.





# **Primary Research**

# Sample Work




### **Primary Research: Hemophilia** US/EU Physician Interviews (Perception of Emicizumab)

Potential in inhibitor patients, SQ administration, and the recent reported SAEs were top of mind with physicians (n=15) when asked about their perception of emicizumab.

> In response to an initial question about their overall perception of emicizumab:

- 9 of 15 physicians viewed the drug as a potential game changer or potentially very beneficial for patients with inhibitors
  - Only 4 physicians initially discussed emicizumab's potential for all hemophilia A patients
- Many physicians also highlighted SQ administration as well as the potential for extended dosing
  - Relative to extended dosing, most physicians and nurses discussed emicizumab as a once weekly drug
- 5 physicians mentioned the reported thrombotic SAEs up front, for some this was the first topic mentioned



• "Will be a fabulous drug for patients with inhibitors. Safety is a major issue, with current information will not use it in patients without inhibitors" – German physician

QUOTES

- "Efficacy reports are good. Sub Q. Patients who have been in trial like the drug. Recent AE report have shaken some of the enthusiasm about the drug" - U.K. Physician
- "Home run for inhibitor patients. For non-inhibitor patients, already have a safe and effective therapy. ACE 910 needs to as safe and effective. Sub Q very important advantage" - U.S. Physician
- "Will be a big splash when it comes out, but still lot of details to be ironed out that could make a difference on how much it's utilized." - U.S. physician

### Primary Research: Gastroenterology KOL Interviews (n=5)

	KOL 1	KOL 2	KOL 3	KOL 4	KOL 5
8. What type of physician sees these patients? Who is the lead treater?	Many come straight to the gastro. This allows the XX to get more attention. Some might mention it to a PCP during a physical or have it noticed incident to something else	I think the majority see a primary care doc. Those seeing a gastroenterologist are going to be the severe ones.	It depends on insurance coverage. Some don't have a choice and are forced to see a PCP, while others have direct access. If XX is the primary complaint, then best to see a gastro.	I'm in private practice and because of insurance the types of patients I see are not going to the PCP for this	Definitely gastros see the more severe cases. Sometimes PCPs feel comfortable and some sti refer to gastro practices.
Consensus	Courses VV anti-outer			s. Mild cases, the majority, a	
conscrisus	, mila cases, ene majority, a	re nanaica by a r er :			
9. Is XX their primary	We see it as both a	There are some, but	Often it is a secondary	If it's effecting the lower	Severe patients usually
complaint?	primary complaint and secondary issue. It is probably evenly distributed.	mostly only the severe ones. <u>The majority of</u> folks are diagnosed incidentally to something else.	situation, especially for mild patients. If XX is the main feature you'd want to see gastro.	<u>quadrant</u> I would say 80% of the time they are coming in for something else. 20% of patients come in just for XX.	bring it up, however I think it's more common that patients don't since most are mild.
Consensus Severe patients and some moderate will present with XX as their primary complaint. For mild cases, XX is commonly observed incide other medical issues. KOLs suggest possibly a 20%/80% split for XX being a primary complaint vs. secondary complaint for patients					

### *in*Thought<sup>®</sup>

M/M/M/M/M/

Earnings Coverage Sample Work



### Earnings Coverage (1) Executive Summary

Coverage of quarterly earnings calls provides key insights on management strategy, pipeline updates, and details from sell-side analyst Q&A.

#### Executive Summary: AbbVie 4Q19 Earnings

#### **Topline Financials**

- FY2019: sales for AbbVie totaled \$33.3 billion, up 2.7%
- 4Q19: sales for AbbVie totaled \$8.7 billion, up 5.3%
- FY2019: sales for Immunology were \$15.2 billion, down (0.8%)
- 4Q19: sales for Immunology were \$5.17 billion, up 5.5%

#### Product Performance

- Humira: FY2019 sales were \$19.2 billion, representing 0.5% growth. 4Q19 sales were \$4.92
   billion, down (2.9%).
  - 4Q19: U.S net revenues of \$3.97B, up 9.8%; international net revenue of \$948M, down (27%). Notable unfavorable impact of international biosimilar competition.
  - FY2019: U.S. sales up 8.6%
- Skyrizi: FY2019 sales were \$355 million. 4Q19 sales were \$216 million.
- Rinvog: FY2019 sales were \$33M. 4Q19 sales were \$47M.

#### Guidance

 AbbVie expects to deliver standalone adjusted diluted EPS for the full-year 2020 of \$9.61 to \$9.71, representing growth of 8.1% at the midpoint.

- AbbVie expects standalone revenue growth approaching 8.0% on an operational basis
- · AbbVie to provide combined guidance with Allergan after the close of the deal

#### **Pipeline**

- Rinvog: 2Q20, PsA regulatory submission
- Rinvog: 2H20, AS submission based on positive data presented at ACR 2019

\*Arrows signify the direction of change for estimates from the previous guarter to the current

- Rinvog: mid-2020, phase 3 data in AD with submission plans for later in 2020
- ABBV-3733: TNF-steroid conjugate early clinical efficacy data expected later this year (2020). Has the potential to serve as a platform across a wide range of indications for RA, IBD, and lupus. AbbVie is excited about this asset.
- Skyrizi: 2021, regulatory submissions for PsA and CD (phase 3 data anticipated in 2020)

#### Q&A

- Management states that Skyrizi and <u>Rinvog</u> launches are ahead of schedule and therefore anticipated to outperform prior estimates.
- Management notes that ABBV-3733, a TNF-steroid conjugate, could deliver transformational results in its phase 2 proof-of-concept trial. This asset is deemed to have tremendous potential.

WW Sales	2017 actual (\$M)	2018 actual (\$M)	2019 actual (\$M)	2020 consensus (\$M)	2021 consensus (\$M)
Humira	18,427	19,936	19,169	19,209 (6)	19,396 (6)
Skyrizi			355	1,088 (6)	J,830 (6)
Rinvoq			47	4 393(5)	485 (6)

#### abb∨ie

### Earnings Coverage (2) Additional Details

*Comprehensive details are provided for revenue drivers, pipeline updates, key presentation slides, and relevant Q&A.* 

biosimilar con		ted in a (28%) de	in 2019. U.S. revenues grew nearly 10 cline for these markets. AbbVie noted							
<ul> <li>FY2019 Humina</li> <li>4019 Skyrizi sa</li> <li>FY2019 Skyrizi :</li> </ul>	ales were \$4.92 billion		ase of (2.9%) On 2020 guidance: - Expect U.S. Humin sales approaching	a to deliver revenue growth of 9%, with international Humira	2 proof-of-concept tria			could deliver transformatio reat potential.	nal results in its phase	
Humira	Revenue 4Q19 WV % growth* \$4.928 0.5%	Revenue FY19 WW 34 growth* \$19.28 (2.9%)	see \$500M Management Comments 4039 U.S. not revenues of \$3.978, up +9.3%; international net • Ustravorable impact of international futures revenues da 72039 • \$4.118 in international asks, down (37.3%) due to browne U.S. sales up 64%	e to biosimilar competition	<ul> <li>A: "ABBV-3733, 1 potency steroid a potential in our p</li> </ul>	lirectly to the activated in reclinical work in our mod	ou look at the basic the cells that are a el systems we see	biology, the ability to drive to loing the damage in these dis	eases really has tremendous hything we've ever seen with othe	r
Skyrizi					•					
Rinvoq	\$33M n/a	Skyrizi in PsA an Pipeline Highlights * Rinvog: 2Q20, Ps * Rinvog: 2H20, A	nd Crohn's disease. A regulatory submission (ankylosing spondylitis) submission based on		is anticipated for Pipeline Updates Obbyle		yx, it was a strong r ell, so that will cont	esult that highlighted high leve inue to drive momentum into	els of response, durability of the space. But having said that inThough	Key Slides abbvie
		* Rinvog: mid-202	0, phase 3 data in AD with submission plans fo	r later in 2020			Regulatory Submissions	Industria II, KOHE (INTEGRATE) Vencesta II, Alk, anti (IV) Vengeni II, Outro Canton Revea PA Revea RA Revea RA Revea RA	Renning AS Eligiptin - Promoving Adultated EM Instructure - Vincetaden MICL (SYMPATICO) Instructure - Vincetaden MICL (SYMPATICO)	
		brazikumab, an i	westigational IL-23 inhibitor in Phase 2b/3 de	s entered into definitive agreements to divest <u>brazik</u> velopment for Crohn's Disease and in Phase 2 develo	pment for ulcerative colitis,		Ph3/Registrational Data Readouts	Elegitir - Horman Add Bask (M Baylar HK Conclusion (ACTIVAT)) Baylar HK Charlow (ACTIVAT)) Baylar HK FH HK HK HK HK Rosen (HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK HK Rosen (HK HK HK HK HK HK HK HK HK HK HK Rosen (HK HK HK Rosen (HK HK H	Indovena PRJ 15. MCI. (DOME) Indovena PRJ of FUNDI, USELINE: Indovena PRJ of FUNDI, USELINE: Indovena i franciska PRJ 15. USE, (SUDI) Indovena i franciska PRJ 15. USE, (SUDI) Vendeske PRJ 2. NB (11. No. (SUNDIE), ABI/-451 PRJ 20	
				ts require FTC and EC approval. Deal is expected to c			Ph3/Registrational Study Starts Early-Stage POC Data Readouts	Verential PSI AND, IN Verential PSI SIDS Restricted PNI SI and in MPI Service Team (Service PSI SIDS) Address SID (PSI Side Side And Side Side Side Management (Service Side Side Side Side Side Side Side Sid	Venesite PLI H MC 113 of Cenvels Venesite PLI H MC 113 of Cenvels Byort PD 40 Byort PD 40 Byort PD 40 Address of Cent Agency PLI Address of Center Address of PPLY ACCEPTs Address of PLY ACCEPTS	54 Diaž Mig Hind MD Faul Alf (2719-
		achieved the prin • Skyrizi: positive I	nary endpoint of ASAS40 response at week 14 wead-to-head data from phase 3 study evaluat	IS 1 trial in which twice as many adult patients with a tversus placebo. ing Skyrizi ( <u>risankizumab</u> ) compared to Cosentyx in a periority for PASI90 at 52 weeks, when compared to	dult patients with moderate to	200	obbvie	17.77	The de (Caller H4) COOPTING (CP H4) Versiens balls Taken Pint ablin 421 (1994), Pint	inThought
		10			in Thought					

### *in*Thought<sup>®</sup>

### **Strategy Workshops**

*in*Thought can lead competitive workshops. The exact focus and scope of these workshops will be determined by the client but could include focusing on competitive position in a specific TA, preparation for a new launch, or for a competitor launch.

Workshop Design	<i>in</i> Thought will work with the client to develop the design of the workshop so that it is appropriate for the attendees and effective at developing insights for the potential market
Pre-read Materials	<i>in</i> Thought will prepare pre-read material for the workshop participants that will include clinical data, trial design, competitor strategy assessments, and other relevant data
Workshop Deck and Material	<i>in</i> Thought will develop, in consultation with the client, the workshop deck as well as any graphics or materials necessary for the performance of the wargame
Pre-workshop Prep	<i>in</i> Thought team members will conduct onsite preparations either the day of or day prior to the workshop
Workshop Execution	<i>inThought</i> will provide a report of the key findings and summaries from the workshop discussions one week after the workshop completion

### inThought®





### inThought's Unique Conference Coverage Technology

In this uncertain environment, conventions and other events are taking precautions amid the COVID-19 outbreak. Some conferences are postponing, while others are providing virtual access. Many companies are restricting travel for employees, preventing them from attending conferences. In addition, many speakers are unable to attend as several leading academic institutions have restricted physician travel for months.

inThought's web-based technology platform, inVision, can help clients **stay on top of cutting-edge scientific information and presentations, in this fluid situation**.

inVision's Conference Module is uniquely suited for biopharma companies to access relevant congress data and analysis, even if they are not attending the convention onsite. Available for an in-person or virtual conference, the system provides organized access to slide decks, presentation notes, and Q&A highlights. Data is maintained on your customized project site for an unlimited number of users. Since the COVID-19 outbreak, we have been adding **new functionality to inVision to accommodate virtual conferences and virtual debriefs**.

inThought can cover the conference for you, or we can work with your current vendor to use only the technology platform.



# Conference Coverage Customized inVision Homepage

The inVision conference homepage is customized based on the client's key intelligence themes (KITs) and key intelligence questions (KIQs).

#### Overview

- Conference coverage schedules are customized based on client keywords and KIQs
- Schedules are uploaded to the inVision platform to allow the inThought analyst to capture presentation/poster images and notes
- Attending internal client members can also access inVision to input their own notes and images
- Presentations/posters are organized by key themes on inVision

			Conference		- LO	ryout			
	FABRY > # WORLD Sympos Analyst: Matt Presi							Q	SEAR ore Search Opti
			Conference Sessions	Confer Post		Conference Documents	Conference Topics	Conference KIQs	Sett
Location: Hyatt Regency Orlan 9801 International Dri Orlando, Florida, USA	ive					+ Sest		+ KOL Contac	t Boot
SCHEDU	JLE		1 Expan	d	7777		MENTS		
Filters Not Set	T Edit 🕅 Virtual 🖸 i	Reset 🔒 Prir	t Color Key			11th Daily Sur 7, 2020	nmary		
Mon, Feb 10	Tue, Feb 11 W	/ed, Feb 12	Thu, Feb 13			12th Daily Sur 7, 2020	mmary		
TIME   ROOM						13th Daily Sur	mmary		R
07:30AM - 11:30AM					WOR	RLD Hard Cop	y Schedule_0	020420.pdf	
Basic Science II: De Attending: Matt Pre	eveloping Therapeutic App esby	roaches in the L	aboratory.		Feb 9 Key Feb 9	Posters (WOF	(LD 2020)		w
01:00PM - 04:30PM						DAILY H	IIGHLIC	CHTS	
Translational Rese	arch I				Feb.	11th Highligh	ts		
Attending: Matt Pre	esby				Feb	12th Highligh	ts		
					Feb	13th Highligh	ts		
04:30PM - 06:30PM Posters (Tuesday)					/k	EYWO	RDS		
Attending: Matt Pres	by				Fabr	у			
g, rider ros					Gau	cher			
06:30PM - 08:30PM					Pom	pe			
Satellite Symposia (	Tuesday Evening)				CNS				
Attending: Matt Pres	thy				A.U.				

#### **Key Themes**

#### KEYWORDS

Fabry	
Gaucher	
Pompe	
CNS	
All	

#### COMPETITORS

Ab	eona	
Au	dentes	
Fre	eline	
De	nali	
	Topic folders to organize presentations by theme	

### *in*Thought<sup>®</sup>

### Conference Coverage Session / Poster Overview

Conference coverage is centralized on inVision, allowing both inThought analysts and internal client team members to simultaneously contribute images, notes, and view schedules.

Session Title / Speaker / Time / Location **Overview** Add Note Notes Settings Conference Conference Conference Conference Sessions Posts Documents Topics KIOs Posts are color coded November 12 2019 04:53PM . Adam Schaffner: based on importance Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus N=362 received therapy, 1:1 randomization 300mg Anifrolumab, IV, Q4W. 🖋 Edit Post Ervthematosus: Results of the Second Phase 3 Randomized Controlled Trial Topics/KIQs and tagged to key Tuesday, Nov 12, 2010 Primary endpoint: BICLA response at week 52. Steroids were tapered Add Highlight Session Name: Late-Breaking Abstract Session Abs #: mandatorily, with no taper allowed between weeks 40 to week 52. Add Images 28 4:30pm - 4:45pn L17 themes 🗣 Add Notes 🔳 Primary endpoint in TULIP 2 was amended from SRI(4) to BICLA before Room Copy URL Hall B1 unblinding. · The analyst's notes and Type: Late-Breaking Abstract Session Abstract BICLA response defined as: Background/Purpose: Anifrolumab, a human monoclonal antibody to the images are compiled in Authors & Speakers: type LIEN receptor subunit 1, had robust efficacy in a phase 2 study in 15% of patients discontinued ani treatment while almost double discontinued Eric Morand et al patients with active SLE. The first phase 3 trial, TULIP-1, did not meet its placebo. primary endpoint. SLE responder index (SRI[4]), but multiple other one central location endpoints, including BILAG-based Composite Lupus Assessment (BICLA) Abstract Link: https://acrabstracts.org/abstract/efficacy-andsuccested clinical benefit. We report results of the second phase a trial of within the relevant anifrolumab. Methods: TULIP-2 (NCT02446899) is a randomized, double-Keywords: blind, placebo-controlled trial that evaluated efficacy and safety of IV anifrolumab Efficacy: anifrolumab 300 mg vs placebo every 4 weeks for 48 weeks in patients with AstraZeneca session moderate to severe SLE despite standard-of-care (SOC) treatment. Patients BICLA reached 48% on treatment vs. 32% placebo. Separation occurred by 4 met ACR SLE criteria and had SLEDAI-2K ≥6 and BILAG >1 A or >2 B. The Attending: Adam Schaffner weeks. primary endpoint was BICLA response at week 52. SOC was stable except Theses notes/images Presentation **Poster Images** can be searched on **Conference Images** 📥 Download PPT inVision by keyword, Email Images View Gallen Manage Images La Download All Images Copy URL priority, and type Team members can 1003 view the entire post, review images, and download or email

inThought

images to colleagues

### **Conference Coverage on Mobile Device**

The inVision conference coverage on a mobile device is similar to the web-based layout. Notes can be directly drafted in inVision or cut and pasted from other apps, such as Notes. Images can be taken in inVision or added through photos on the mobile device.



inVision icon

Mobile layout	Notes function	Adding images	
Sat, Oct 06	8 8 8		
TIME   ROOM	Association of phosphorylated		
11:45AM - 01:15PM   Auditorium	neurofilament heavy chain (pNF-H) with nusinersen treatment of SMA: analyses from		
Selected oral presentations I - New genes, functions and biomarkers (0.1-6) Attending: Chris Martin	Industries of dealers of on an analysis from the eNDEAR and CHERISH studies       B     I       U     Verdana       11pt     -       I     -		
11:45AM - 01:15PM   Auditorium			
O.5 Association of phosphorylated neurofilament heavy chain (pNF-H) with nusinersen treatment of SMA: analyses from the ENDEAR and		+ Select Files to Upload	
CHERISH studies	0 WORDS POWERED BY TINY ایز		
Attending: Chris Martin	O Add Highlight Priority: High	Take Photo or Video	ſ
Biogen		Photo Library	C
+ Images + Notes	Save Save and Assign	Browse	
02:30PM - 04:00PM   Poster area		Cancel	_

*in*Thought<sup>®</sup>

### Conference Coverage Booth Coverage

Booth coverage allows the inThought analyst to capture key messaging themes that are stored on inVision.

**Photos** 





#### Commentary

- Boehringer Ingelheim has 3 booths. One main booth focused on Spiriva and it is also one of the largest in the hall.
- A mist from a large Respimat inhaler flows in the booth.
- Key messaging highlighted that "50% of patients remain symptomatic" and promotes add on TIO."
  - "Spiriva significantly reduced the risk of asthma worsening - 31% risk reduction"
  - "Stay in front of asthma"
  - "New Spiolto Respimat for further improvement beyond Spiriva Respimat"
- Even the floor is a video of growing tree roots and huge curved screens rise from this presenting information on Spiolto. The metaphor is that Spiriva was the roots. A key message of Spiolto is "An advance in COPD care built on strong roots".
- Messaging on the screens focused on the rapid onset and improvement in LF compared to Spiriva.
- A wall focused on Respimat had a screen highlighting a study Respimat with other devices (TurboHaler etc.) and this indicated a > 50% deposition to the lungs, much better than any other device. The booth also highlights all of the drugs available with Respimat (Spiriva, Spiolto, Striverdi, CombiVent, etc.) Respimat is the only inhaler promoted.
- 30-35% of the booth focused on IPF.

#### inVision Cloud Storage






### *in*Thought<sup>®</sup>

### Conference Coverage Key Intelligence Questions (KIQs)

inVision maintains a repository of client's KIQs and relevant answers.

KEY INTELLIGENCE QUESTIONS		
Question	Answer	
Are the results seen in the EMPA-REG OUTCOME trial considered a SGLT- 2 class effect?	The CVOT results in the canagliflozin CANVAS trial, which were similar to the empagliflozin CVOT results, suggest that the CV benefits seen in both trials may be viewed as a SGLT2 inhibitor class	
How does the diabetes community think about changing CVOTs?	Potential changes include: using a lower risk population including primary prevention patients, longer follow-up, modifying endpoints including including heart failure as a primary endpoint and the	
How will CVOTs affect the prescribing of diabetes drugs?	Presenters recommended treating diabetes patients with CVD or high CVD risk as a specific category when choosing 2nd line therapy by prescribing a diabetes drug which as shown a CVD risk reduction	
<u>How will diabetes</u> drug CVOTs affect guidelines?	Presenters advocated changing ADA guidelines to include diabetes drug CVOTs and CV risk in the choice of a second line therapy after metformin.	



### inThought

### Virtual Conference Coverage

The inVision conference site has features enabling coverage of virtual conferences. These features also allow for attending conferences "virtually" as well as conducting virtual conference debriefs

#### Overview

- inVision provides links to virtual presentations, whether the conference is virtual or if team members are attending "virtually."
- The debrief function allows the selection of key information, including pictures of data, to be combined with summary text and analysis in a virtual debrief. Insights from the debrief can be incorporated into the conference project.
- A virtual conference tour can be constructed with key summaries and pictures to provide a quick summary of conference highlights with the ability to delve into more detailed information

#### Virtual Debrief/Conference Summary

Priday, Oct 05, 2018 330pm - 500pm	Abs#: P255	Session Name:	Poster session 3	View Full Post	Next Post
Type: Posters					
Authors & Speakers:					
E. Mercuri					
Summary					

 Median change in MFM-32 at 12 months of treatment was 313 points 417 points in the 2-11 yrs old group and 2.08 points in the 12-24 yrs old group

· A review of currently available safety data did not show any clinically significant adverse findings compared with baseline

#### **Key Slides**

SMA Type 2 & 3 patients showed improvements in motor function

#### Risdiplam treatment leads to stabilization or improvements in motor function in patients with Type 2 or 3 SMA

Endpoint : (At 12 months of treatment)	>12 months Treatmen	onths Treatment		
MFM	All patients (n=30)*	Aged 2–11 (n=17)	Aged 12-24 (n=13)	
Total MFM change from baseline, mean (SD)	2.47 (4.17)	3.31 (4.5)	1.36 (3.57)	
Total MFM change from baseline, median (range)	3.13 (-7.3–11.5)	4.17 (-6.3–11.5)	2.08 (-7.3–5.2)	
Proportion of patients who achieve improvement (i.e., a change from baseline in MFM score ≥1), % (n)	70 (21/30)	76.5 (13/17)	61.5 (8/13)	

#### **Virtual Presentations**

#### VIRTUAL PRESENTATIONS

#### Thu Oct 04

Avexis symposium - Gene Re Treatment Paradigm Shift in 2:00pm - 3:30pm	
Our Knowledge from Basic S Multidisciplinary Team.	-
7:30am - 9:00am Fri Oct 05	Virtual Presentation »
PTC Therapeutics symposius landscape in DMD and SMA.	
2:00pm - 3:30pm	Virtual Presentation »

### *in*Thought<sup>®</sup>

### Conference Coverage Daily Debrief Example



#### American Society of Hematology

Helping hematologists conquer blood diseases worldwide

#### December 8th Highlights

Sunday highlights from ASH included NHL data on the combination of obinutuzumab/lenalidomide and the Genentech/Roche CD20:CD3 bispecific mosunetuzumab (Plenary Session).


#### Indolent non-Hodgkin Lymphoma


Abs. 348: A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan Fowler (MD Anderson Cancer Center) gave a morning presentation on a Phase 1/2 trial studying lenalidomide plus obinutuzumab in relapsed indolent lymphoma patients. 86% of enrolled patients had FL (n=57) with a minority of MZL and SLL patients also under study. The majority of patients were on their 3rd line of therapy or greater. Very impressive responses were observed in FL with an ORR of 100% (CR rate 75%) and 74% of patients experiencing PFS at 24 months. For the overall indolent NHL population the OS at 24 months was 94%. Additionally, the following subset analyses were provided for the overall indolent NHL population:

- POD24: ORR = 96% (CR rate 66%)
- ≥3 lines: ORR = 97% (CR rate 68%)
- Rituximab refractory: ORR = 100% (CR rate = 63%)

The toxicity profile was manageable with the most common Grade 3-4 AEs being neutropenia (21%), infection (14%), and thrombocytopenia (11%).





#### Product Theater: The Role a New Combination Therapy in Previously Treated Follicular Lymphoma

#### Sponsor: Celgene

Attendance was moderate for this Celgene product theater, with only about 50% of seats filled. During this talk the AUGMENT thal data assessing the combination of lenalidomide/rituximab (R<sup>2</sup>) in previously treated FL was reviewed. Key commentary from the presenter mentioned that neutropenia was easily managed with dose modifications and growth factor support. It was noted that the associated neutropenia was not necessarily considered a direct toxicity but more of a maturation risk. Further, the presented commented that, "there was not much in the way of Grade 3-4 AEs with this treatment." No new efficacy or solety data was presented.

	All Advertue Reactions		Grade 2-4 Advance Reactions*	
				Revenue
Bood and funghatin disorders, n (%) Mendespenser <sup>4</sup> Anterspenser <sup>4</sup> Anterspenser <sup>4</sup> Anterspenser <sup>4</sup> Langhopense Langhopense Fabrille numberspense <sup>4,6</sup>	102 (198) 30 (20) 20 (19) 20 (15) 8 (4.5) 9 (2.6)	40 (02) 17 (0) 0 (4.4) 0 (4.4) 14 (0) 14 (0)	60.05m 12.07 8.04.51 4.12.55 5.02.85 5.02.85	28.000 3.0.71 1(c.1) 2(1.1) 2(1.1) 1(c.1)



# **Social Media Monitoring**


# Sample Work



### **Drug-Specific Social Media Metrics**

Tailoring the information monitored to your needs allows you to better understand your overall market.


#### **Overall Tweet Volume During ACC 2020\***



35

### Social Media Details by Drug

During medical meetings, following data volume by day as well as what is being said can allow you to understand how your data are being received and stay on top of competitors.



仚



Ben Weintraub, PhD bweintraub@inthought.com 1.646.331.9234

After completing his training in immunology and biochemistry, Dr. Weintraub began work as a financial analyst in 2000. Collaborating with Dr. Henderson, Dr. Weintraub co-founded BiotechTracker, an online tool for investors. In 2004, he became a licensed security analyst with Hibernia Southcoast Capital covering the biotechnology sector, and later performed the same role at Variant Research. In 2006, Dr. Weintraub joined Dr. Henderson and Dr. Zuckerman at Reuters Insight, providing analysis of drug development and trends in medicine to professional investors. Dr. Weintraub's team moved to inThought in January 2009. Through a divestiture by Wolters Kluwer, inThought and Source Healthcare Analytics became part of Symphony Health Solutions, a healthcare information company. inThought Research LLC formed a stand-alone company in May 2014.

Prior to 2000, Dr. Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell. Dr. Weintraub performed biochemistry and immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra, Australia. He earned his doctorate in Biology from the University of California, San Diego, and a Bachelor of Science in Life Science from the Massachusetts Institute of Technology.

37

*in*Thought<sup>®</sup>

www.inthought.com



Adam Schaeffer, MBA aschaeffer@inthought.com 1.301.602.3297

Mr. Schaeffer is a founding partner of inThought Research. He is responsible for identifying and developing new business opportunities, as well as expanding the presence of the company and its brand. Mr. Schaeffer has over 20 years of experience in healthcare industry consulting.

Prior to inThought, he served as Director of Institutional Sales at Symphony Health Solutions where he oversaw key pharmaceutical accounts and launched the Wall Street practice. Mr. Schaeffer also served as Business Development Manager at Wolters Kluwer Health. In this role, he helped to build an independent research group and life science consulting business. He was previously US Director of Sales and Marketing at Informa. Mr. Schaeffer received his Master in Business Administration from the Robert H. Smith School of Business and has a Bachelor of Arts in Sociology from the University of Maryland.





Doug Foster dfoster@inphronesis.com 1.508.414.9819

Doug Foster is focused on the development and improvement of the inVision system. An MIT graduate, Doug brings a unique combination of entrepreneurial experience, knowledge and learning management system knowledge, and enterprise system integration experience. Before joining inPhronesis, Doug led teams at InterSystems and Boston Scientific, where he was responsible for implementing and managing learning and knowledge management systems for employees, partners and customers for as many as 25,000 users globally. Previously, Doug was the VP of Services for Click2Learn (now SumTotal Systems) where he led a team responsible for the development of custom eLearning for clients including Fidelity and Microsoft.

> inThought<sup>®</sup> www.inthought.com



Chris Martin, MSc, MBA cmartin@inthought.com 1.703.725.5820

Mr. Martin has over 18 years of experience in healthcare industry consulting, finance, and healthcare policy. He previously served in health policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer for the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.

Mr. Martin was the Vice President of Research at Lese Investments LLC, a healthcare focused investment company, and co-portfolio manager at Cameron Capital. He has also performed consulting in the healthcare industry at Biotech Tracker and McKinsey and Company. Mr. Martin has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science, with distinction, in Mechanical Engineering from Cornell University.





Amanda Weyerbacher, PhD aweyerbacher@inthought.com 1.917.612.2939

Prior to joining *in*Thought, Dr. Weyerbacher was a scientific consultant to biotechnology companies, providing scientific and regulatory analysis of compounds and distinct therapeutic combinations. She has previously worked as a Senior Scientist at L'Oreal Research and Development. In this role, she managed the clinical testing program of multiple consumer products and supported cross-functional teams with scientific leadership and expertise to facilitate blockbuster product launches.

Dr. Weyerbacher graduated from Skidmore College with a Bachelor's degree in Biology-Chemistry before receiving a PhD in Pharmacology from Weill Cornell Medical College. Her dissertation research focused on the identification of critical pain signaling proteins, cytokines and immune/central nervous system interactions as relevant pharmacological targets for clinical pain control. In between college and graduate school, Dr. Weyerbacher was a Clinical Research Study Assistant at Memorial Sloan Kettering Cancer Center. In this role, she managed an active clinical trial program, defining and monitoring project scope, timelines and deliverables from project initiation to close-out. She has presented her research in pharmacology, neuroscience and oncology at several scientific conferences. Dr. Weyerbacher is the immediate past President and active member of the MetroNY Chapter of the Association for Women in Science (AWIS).



*in*Thought<sup>®</sup>

www.inthought.com



Adam Schaffner, PhD aschaffner@inthought.com 1.818.427.3385

Dr. Schaffner joined inThought in 2017 after earning his PhD in Biomedical Sciences at the Mount Sinai School of Medicine in New York, where he developed novel therapeutic strategies to target Parkinson's Disease and other neurodegenerative disorders.

While completing his dissertation, he worked as a venture intern at Celdara medical, where he conducted due diligence on academic innovations for partnership, development, and investment opportunities. Beyond the science, Dr. Schaffner has held various leadership roles as a student at Mount Sinai, and served as Co-founder and Co-chair of the Trainee Health and Wellness (THAW) Committee, which tackles systemic issues endangering the mental well-being of academic research trainees. He earned his Bachelor of Science in Biochemistry at the University of California, Los Angeles.

*in*Thought<sup>®</sup>



Julie Hoggatt jhoggatt@inthought.com 1.504.220.9366

Ms. Hoggatt covers the medical technology, women's health, aesthetics and some infectious disease indications. Ms. Hoggatt comes from Noble Financial where she was the Senior Medical Technology analyst. Prior to Noble, Ms. Hoggatt helped start the independent research firm, Variant Research with Dr. Weintraub and Dr. Henderson.

Before Variant she worked at Hibernia Southcoast Capital, where she was also a Medical Technology Analyst and a Vice President of Equity Research. Ms. Hoggatt began in the investment industry as an associate equity analyst at Morgan Keegan & Company covering medical devices and earned the title Associate Vice President of Equity Research. Her professional career has been focused on the healthcare sector and has included in-depth coverage of over thirty different companies in the Medical Technology and Medical Device industries, allowing her to share a wealth of knowledge and insight with our clients. Ms. Hoggatt received her Bachelors of Business Administration and Master of Accountancy from Millsaps College in Jackson, Mississippi.



www.inthought.com



Michelle Rivera, MBA, PhD <u>mrivera@inthought.com</u> 1.917.575.1372

Dr. Rivera joined inThought in early 2019. She completed her PhD research at Columbia University Medical Center in Pathobiology and Molecular Medicine. Her work at the Center for Motor Neuron Biology and Disease focused on drug development for the neuromuscular pediatric disorder, Spinal Muscular Atrophy (SMA).

Prior to Columbia, Dr. Rivera was a research associate at Cold Spring Harbor Laboratories, where she specialized in molecular research of pre-mRNA splicing mechanisms. She also earned an MBA in Finance and a Master of Science in Biophysics from the University of Barcelona.





Roshni Basu, PhD rbasu@inthought.com 1.646.942.6989

Dr. Basu joined inThought in 2015, after completing her post-doctoral studies in Immunology at Memorial Sloan-Kettering Cancer Center, where she studied mechanisms potentiating cytotoxic T cells. While at MSKCC, she also worked as a Life Science Analyst for a boutique consulting firm, providing due diligence on diverse therapeutic areas to hedge funds and mutual funds.

In addition to research, Dr. Basu has regularly been involved in several public health and science education projects in the New York City area. She earned her PhD in Cell Biology from Columbia University in New York and a B.Sc. in Biology from McGill University in Montréal.

inThought<sup>®</sup> www.inthought.com



Samantha Crofskey, BSc scrofskey@inthought.com 1.732.455.9121

Ms. Crofskey has over 12 years of experience in medical writing, account management and pharmaceutical industry consulting. She provides coverage for the immunology and neurology sectors, including everything from emerging targets and drug development to market analysis and customized business intelligence.

Prior to joining inThought, Ms. Crofskey worked as a medical writer for Wolters Kluwer in Auckland, New Zealand before moving to London to work as an Editorial Project Manager at Current Medicine Group, a Springer Healthcare company, and later, as an Editorial Project Manager at BioScience Communications. Ms. Crofskey returned to Wolters Kluwer in 2010 and subsequently joined the inThought team as a consultant in 2011. Ms. Crofskey earned her Bachelor of Science in Neuroscience and Pharmacology from the University of Otago in New Zealand.





Matt Presby, PhD mpresby@inthought.com 1.732.690.4119

Dr. Presby joined inThought in 2019. Previously, he worked for a boutique biopharma consulting firm and also completed an internship in equity research at Leerink Partners. In these roles, he has developed experience in business development assessments, forecasting, and market access.

Dr. Presby received his Ph.D. in Immunology from the Johns Hopkins School of Medicine where his thesis work focused on the discovery of biomarkers in autoimmune disease and T Cell functionality. Additionally, while at Hopkins he was a co-founder of the Johns Hopkins Biotech Investment Group (JHBIG) which focuses on preparing students for careers in equity research and venture capital. He earned his B.S. in Biology from Gettysburg College.





Lavan Khandan, PhD Ikhandan@inthought.com 1.860.965.8007

Dr. Khandan joined *in*Thought Research in 2019. He has held previous positions as a Fellow at a life science consulting firm and as a Scientist at Editas Medicine. In these roles, Dr. Khandan built expertise in asset scouting, evaluating rare diseases and therapeutic areas, and building market access and commercial viability assessments.

Dr. Khandan received his Ph.D. in Molecular, Cellular, and Developmental Biology from the University of Colorado, Boulder. His doctoral research focused on signaling and growth factors governing retinal vascularization. He has extensive experience in CRISPR/Cas9 gene editing, stem cell differentiation, and cell therapies. Dr. Khandan received his A.B. in Chemistry from Dartmouth College.

